Rare neurological disorders
Intrabio Limited focuses on rare neurodegenerative and movement disorders, with research activity centred on conditions that affect coordination, balance, and motor control. Its clinical programme includes studies in Ataxia Telangiectasia, CACNA1A disorders, and Niemann-Pick disease type C.
- Ataxia Telangiectasia
- CACNA1A disorders
- Niemann-Pick disease type C
The sponsor’s research portfolio is concentrated on neurological conditions with limited treatment options and overlapping features of ataxia and impaired motor function.
Ataxia-focused clinical research
Clinical trials supported by Intrabio Limited place strong emphasis on ataxia as a core therapeutic domain, using outcome measures relevant to gait, coordination, and functional mobility. This includes work across both inherited cerebellar disorders and broader syndromes presenting with progressive movement impairment.
- Ataxia assessment
- Cerebellar dysfunction
- Motor coordination impairment
Research activity in this area reflects a clear interest in neurological symptom control and functional improvement in chronic rare disease settings.
Inherited metabolic and lysosomal disease
The sponsor is also active in inherited metabolic disorders, particularly lysosomal storage disease research involving Niemann-Pick disease type C. This area addresses neurological and systemic disease manifestations linked to abnormal cellular processing and progressive disability.
- Lysosomal storage disorders
- Niemann-Pick disease type C
- Neurovisceral disease
These studies position the sponsor within a therapeutic field that combines neurology, metabolism, and rare disease medicine.
Therapeutic interest in N-Acetyl-L-Leucine
Intrabio Limited’s clinical research centres on N-Acetyl-L-Leucine as a treatment candidate across multiple rare neurological diseases. The trials examine its role in managing chronic symptoms associated with ataxia and related neurological impairment.
- N-Acetyl-L-Leucine
- Chronic neurological symptom management
- Rare disease therapeutics
The sponsor’s funded studies are directed toward conditions where preserving mobility, coordination, and neurological function is a major clinical concern.
